A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse-Reference-Cited by-同舟云学术

A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse

Published:2016-11-30 Issue:12 Volume:23 Page:3035-3044
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Prat Aleix,Lluch Ana,Turnbull Arran K.,Dunbier Anita K.,Calvo Lourdes,Albanell Joan,de la Haba-Rodríguez Juan,Arcusa Angels,Chacón José Ignacio,Sánchez-Rovira Pedro,Plazaola Arrate,Muñoz Montserrat,Paré Laia,Parker Joel S.,Ribelles Nuria,Jimenez Begoña,Bin Aiderus Abdul Aziz,Caballero Rosalía,Adamo Barbara,Dowsett Mitch,Carrasco Eva,Martín Miguel,Dixon J. Michael,Perou Charles M.,Alba Emilio

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response;Nature Communications;2024-07-11

2. Moving toward precision medicine to predict drug sensitivity in patients with metastatic breast cancer;ESMO Open;2024-03

3. Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer;Cancer Treatment Reviews;2024-02

4. The Role of Nodes and Nodal Assessment in Diagnosis, Treatment and Prediction in ER+, Node-Positive Breast Cancer;Journal of Personalized Medicine;2023-10-08

5. Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristics;Clinical Breast Cancer;2023-06